Concentrations of CSF hypocretin-1 (formerly orexin A) have been measured in many
patients with sleep or neurological conditions. Low CSF hypocretin-1 is most predictive of …

Orexin, a small neuropeptide released from neurons in the hypothalamus with widespread
projections throughout the central nervous system, has broad biological roles including the …

A recent study showed that people evaluate products more positively when they are
physically associated with art images than similar non-art images. Neuroimaging studies of …

Almorexant, a dual orexin receptor antagonist potentially representing a new class of sleep‐
promoting compounds, was administered in an ascending single‐dose study to evaluate …

Orexins including two peptides, orexin‐A and orexin‐B, are produced in the posterior lateral
hypothalamus. Much evidence has indicated that central orexinergic systems play numerous …

Narcolepsy is a clinical condition characterized mainly by excessive sleepiness and
cataplexy. Hypnagogic hallucinations and sleep paralysis complete the narcoleptic tetrad; …

The accumulation of adipose tissue represents one of the characteristics of obesity,
increasing the risk of developing correlated obesity diseases such as cardiovascular …

Obstructive sleep apnea is the most common sleep-related breathing disorder. Repetitive
episodes of the obstructive respiratory events lead to arousal, sleep fragmentation, and …

Until recently, olfactory dysfunction was an unknown feature of narcolepsy. Orexin A, also
called hypocretin-1, is abnormally decreased or undetectable in the cerebrospinal fluid of …

The objectives of this study were to investigate the multiple-dose tolerability, safety,
pharmacokinetics, and pharmacodynamics of the dual orexin receptor antagonist …